Multimorbidity predicts quality of life but not motor severity in early Parkinson\u27s disease by Gravell R et al.
1 
 
Multimorbidity predicts quality of life but not motor severity 
in early Parkinson's disease 
 
R Gravell1, G W Duncan2,3, T K Khoo4, D J Burn1, A A Sayer3,5,6, R.A. Barker7, R A 
Lawson3,5, A J Yarnall3,5,6  
 
 
1 Faculty of Medical Science, Newcastle University; 2 Centre for Clinical Brain 
Sciences, University of Edinburgh; 3 Institute of Neuroscience, Newcastle University; 
4 School of Medicine & Menzies Health Institute Queensland, Griffith University, 
Australia; 5 Newcastle Institute for Ageing, Newcastle University; 6 AGE Group, 
Newcastle University; 7 Department of Clinical Neurosciences, Cambridge Centre for 
Brain Repair   
  
Corresponding Author: 
Rhys Gravell 
Faculty of Medicine 
Newcastle University 
Newcastle upon Tyne 
NE4 5PL  
rhys-gravell@hotmail.com  
 
Abstract Word Count: 98 
Word Count (Excluding abstract): 1499 
Number of tables: 2 
Number of references: 13 
Keywords: Multimorbidity, Parkinson's disease, Quality of life, Motor severity 
 
 
  
2 
 
Abstract 
Recent guidance by the National Institute for Health and Care Excellence (NICE) 
focuses on the management of people with multimorbidity, including Parkinson's 
disease (PD). To date there has been little exploration of this in neurodegenerative 
diseases. This study aimed to explore the associations between multimorbidity, 
motor severity and quality of life (QoL) in early PD. Regression analyses determined 
whether multimorbidity was significantly associated with disease severity and QoL. 
Multimorbidity was a small but significant predictor of QoL in people with incident PD, 
but not motor severity, suggesting that they may benefit from a tailored 
multidisciplinary approach to care. 
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Introduction 
Parkinson’s disease (PD) is characterised by both motor and non-motor symptoms 
(NMS) [1]. It is primarily a disease of older people; thus, many will have comorbid 
disease at the time of diagnosis. Multimorbidity is an evolving concept of particular 
relevance in later life [2] and to date there has been little study of this in PD. 
Multimorbidity in PD negatively impacts on many aspects of the disease, including 
quality of life (QoL) [1]. Multimorbidity is defined as having two or more concurrent 
chronic physical or mental conditions, and affects 75% of those over 70 years [3, 4]. 
Risk factors include increasing age, low education, and alcohol intake [5]. 
Multimorbidity has a deleterious and dose-response effect on cognitive function, 
particularly in those at risk of cognitive impairment [6]. It is associated with increased 
utilisation of healthcare resources, functional disabilities and hospitalisation [5, 7].  
Secondary care is often specific with conditions being dealt with in isolation leading to 
fragmented care [6], therefore the National Institute for Health and Care Excellence 
(NICE) have produced guidelines on multimorbidity, identifying those that may benefit 
from multidisciplinary input [4]. These include those with two or more chronic physical 
or mental health conditions or symptom complexes. Parkinson’s disease encompasses 
symptom complexes such as frailty and pain, therefore is a key target disease from the 
NICE guidelines. McLean et al. [8] recently highlighted the need for targeted research 
into multimorbidity in older people.  
The aim of this study was to explore the associations between multimorbidity, 
severity of motor symptoms and QoL in people with early PD. We hypothesized that 
those with greater multimorbidity scores would have poorer QoL and psychological 
health. 
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Methods 
This was conducted as part of the Incidence of Cognitive Impairment in Cohorts with 
Longitudinal Evaluation – Parkinson’s disease (ICICLE-PD) study, a longitudinal 
observational study conducted over two sites in Newcastle-upon-Tyne and 
Cambridgeshire. Participants with newly diagnosed idiopathic PD (n=154), plus age- 
and sex- matched unrelated healthy controls (n=99) were recruited from community 
sources, with the initial aim of comparing multimorbidity in PD with controls [9]. 
Neurological assessment consisted of a standardised examination. Motor severity was 
rated with the MDS Unified Parkinson’s Disease Rating Scale (MDS-UPDRS-III), and 
Hoehn and Yahr scale. A global measure of health-related QoL was assessed using 
the Parkinson’s disease Questionnaire (PDQ-39), and depression with the Geriatric 
Depression Score (GDS-15). Global cognition was assessed using Montreal Cognitive 
Assessment score (MoCA).  Levodopa equivalent daily dose (LEDD) was calculated 
using Thompson et al.’s formula [10]. Non-motor symptoms were determined using the 
NMS Questionnaire (NMSQuest). Multimorbidity criteria were applied to the full 
medication list and past medical history. The presence of multimorbidity was defined 
in four different ways: 
1. A binary classification of multimorbidity based on the definition given in the NICE 
guidelines [4]. 
2. Disease count using International Classification of Primary Care-2 (ICPC-2) 
conditions. 
3. Medication counts of all prescribed and non-PD medications. 
4. Age-adjusted Charlson Comorbidity Index (CCI). 
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Using IBM SPSS V24, data were examined for normality of distribution using 
Kolmogorov-Smirnov’s test and visual histograms. Mann-Whitney U- and t-tests were 
performed as appropriate. Pearson’s Chi squared tests were used to compare 
categorical data. Spearman’s rank correlations were used to assess correlation. 
Hierarchical linear regression analysis was conducted to identify predictors of MDS-
UPDRS-III and PDQ-39 scores. After removal of non-significant predictors, 
multimorbidity measures, as described above, were individually added to the basic 
models to determine whether they were significant independent predictors of motor 
disease and QoL. Given the exploratory nature of the study, no adjustments for multiple 
testing was made.   
 
Results 
Participants with PD (n=154, mean disease duration 6.0±4.6 months) and controls 
(n=99) were well-matched for age, gender and years of education (Supplementary 
Data). Participants with PD demonstrated a higher level of global cognitive impairment 
as measured by MoCA, in addition to greater depression scores. The mean number of 
NMS (8.4±4.4 vs 2.9±2.6, t=-10.0, p<0.001) and mean number of all prescribed 
medications (4.9±3.1 vs 3.1±2.8, t=-4.8, p<0.001) were significantly greater in PD 
patients. 
The burden of multimorbidity did not differ between PD and control participants as 
measured by the mean ICPC-2 conditions (2.3±1.8 vs. 2.4±1.6, t=-0.5, p=0.632), age-
adjusted CCI (1.1±1.9 vs. 0.9±1.7, t=-1.1, p=0.253), NICE criteria (58.4% vs. 58.6%, 
t=-0.2, p=0.982) or medication counts (excluding PD drugs) (3.7±3.1 vs. 3.1±2.8, t=-
1.3, p=-.182). No significant differences in comorbidities were seen between PD 
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participants and controls, with the exception of cerebrovascular disease (7.1% vs. 0%, 
p<0.05).  
Univariate linear regression analysis showed that more severe motor severity using 
the MDS-UPDRS-III score was associated with significantly higher GDS-15 scores 
(p<0.001) and lower MoCA scores (p<0.05). Both GDS-15 and MoCA scores were 
included in the basic model (table 1). The addition of individual multimorbidity 
measures did not significantly improve the model. 
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Table 1 Predictors of MDS-UPDRS-III score 
 
 β SE t p 
95% CI for β 
 Lower Upper 
Basic 
Modela 
MoCA -0.147 0.274 -1.813 0.072 -1.037 0.045 
GDS-15 0.288 0.380 3.553 0.001 0.598 2.099 
 
Basic Model + 
Disease Countb 
0.014 0.573 0.161 0.872 -1.040 1.225 
 Basic Model + 
Medication Count 
(Non-PD 
medications)c 
0.038 0.332 0.446 0.656 -0.509 0.806 
Basic Model + 
Medication Count 
(All Prescribed 
medications)d 
0.026 0.334 0.308 0.759 -0.557 0.762 
Basic Model + Age-
adjusted CCIe 
-0.071 0.530 -0.868 0.387 -1.509 0.588 
Basic Model + NICE 
guideline-defined 
multimorbidity 
0.003 2.082 0.035 0.972 -4.046 4.191 
a R=0.335, Adjusted R2=0.099, F=8.598, p<0.001 
b R=0.335, ∆R2=0.000, F=5.699, p=0.001 
c R=0.337, ∆R2=0.001, F=5.764, p=0.001 
d R=0.336, ∆R2=0.001, F=5.725, p=0.001 
e R=0.342, ∆R2=0.005, F=5.972, p=0.001 
f R=0.335, ∆R2=0.000, F=5.690, p=0.001 
Significant values indicated in bold. 
Abbreviations: MDS-UPDRS-III = Movement Disorder Society Unified Parkinson’s 
Disease Rating Scale III; MoCA = Montreal Cognitive Assessment; GDS-15 = 
Geriatric Depression Scale-15; CCI = Charlson Comorbidity Index. 
 
Univariate analysis revealed that younger age, higher GDS-15 scores and higher 
MDS-UPDRS-III scores significantly predicted of poorer QoL (Table 2); these were 
included in the basic model, in addition to years of education which demonstrated a 
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trend for prediction. Gender was also included in the basic model as gender difference 
in QoL have been previously reported. These accounted for 51.3% of the variance 
seen in PDQ-39 scores. The addition of all multimorbidity measures improved the 
predictive ability of the basic model except for NICE guideline-defined multimorbidity 
(Table 2, p<0.05 for all), demonstrating that multimorbidity was associated with lower 
QoL. The multimorbidity measures accounted for small changes in the models (1.5-
2.5%); medication count of all prescribed medications had the most influence on QoL 
(∆R2=0.026). 
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Table 2 Predictors of PDQ-39 score 
 
 β SE t p 
95% CI for β 
 Lower Upper 
Basic 
Modela 
Age -0.132 0.091 -2.054 0.042 -0.368 -0.007 
Gender 0.113 1.792 1.885 0.062 -0.166 6.923 
Years of Education -0.128 0.239 -1.960 0.052 -0.942 0.004 
GDS-15 0.539 0.338 8.651 <0.001 2.259 3.598 
MDS-UPDRS-III 0.290 0.074 4.521 <0.001 0.189 0.484 
 
Basic Model + 
Disease Countb 
0.140 0.496 2.239 0.027 0.130 2.092 
Basic Model + 
Medication Count 
(Non-PD 
medications)c 
0.143 0.286 2.300 0.023 0.093 1.223 
Basic Model + 
Medication Count 
(All Prescribed 
medications)d 
0.180 0.280 2.960 0.004 0.276 1.384 
Basic Model + Age-
adjusted CCIe 
0.149 0.449 2.547 0.012 0.257 2.032 
Basic Model + NICE 
guideline-defined 
Multimorbidityf 
0.036 1.724 0.610 0.543 -2.355 4.459 
a R=0.728, Adjusted R2=0.513, F=30.050, p<0.001 
b R=0.743, ∆R2=0.015, F=30.263, p<0.001 
c R=0.744, ∆R2=0.016, F=30.363, p<0.001 
d R=0.751, ∆R2=0.026, F=31.614, p<0.001 
e R=0.746, ∆R2=0.020, F=30.795, p<0.001 
f R=0.734, ∆R2=0.001, F=28.591, p<0.001 
Significant values indicated in bold. 
Abbreviations: PDQ-39 = Parkinson’s Disease Questionnaire-39; GDS-15 = Geriatric 
Depression Scale-15; MDS-UPDRS-III = Movement Disorder Society Unified Parkinson’s 
Disease Rating Scale III; CCI = Charlson Comorbidity Index. 
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Discussion 
Multimorbidity is an evolving concept, and to our knowledge, this is the first study to 
investigate the association between multimorbidity and the severity of PD in a large incident 
cohort, where we found a small but significant effect on QoL.  
The burden of multimorbidity did not differ between PD participants and controls, except for 
when measured using a medication count of all prescribed medications, differing from 
previous findings [11].This may be accounted for by our use of the ICPC-2 conditions, which 
are more selective, minimising the overlap with NMS. 
There is no universal tool for measuring PD-related multimorbidity. However, recent 
literature tends to use age-adjusted CCI as it is considered to be a robust, evidence-based 
method for the prediction of long-term QoL [12]. Medication counts are simple, however, 
given the multi-system nature of PD, the mean count of all prescribed medications was 
higher in patients with PD compared with controls. Non-PD medication count may improve 
accuracy in assessing multimorbidity in PD patients, eliminating PD-burden as a confounder. 
We did not find an effect of multimorbidity on motor severity. This may relate to the fact that 
we were studying an incident cohort, with accordingly early disease (mean disease duration 
= 6.0 months), reducing the heterogeneity of motor severity and the ability to detect the 
possible predictive powers of multimorbidity measures. 
Leibson et al. [11] demonstrated a dose-response effect of comorbidities on worsening 
outcomes relating to mental disorders. Mitnitski et al. [13] provide a model of deficit 
accumulation, where the more pathophysiological processes an individual accumulates, the 
more vulnerable they become. Despite referring to mortality this may explain the relationship 
seen between multimorbidity and QoL. Multimorbidity may lead to physical or mental stress, 
resulting in a restricted capacity to function and lower QoL. A unified approach to care 
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proposes a multifactorial theory for addressing patient outcomes, addressing the role of 
dynamic interactions between physiological functions. Outcomes are linked, and addressing 
individual outcomes, such as pathophysiological process, will in turn affect other patient 
outcomes in terms of morbidity and mortality exemplifying the importance of multimorbidity 
on QoL in early PD.  
Clinically, multimorbidity is important because it is common and affects QoL Multimorbidity 
has an impact upon recruitment to clinical trials and carer strain. Thus, identifying it offers 
targets for medication rationalisation, multidisciplinary approach to care, and re-thinking of 
clinical trial design. 
This study included a large well-defined cohort of participants with incident PD, and age- 
and sex-matched controls undergoing rigorous testing with validated research tools. Not all 
PD participants were dopamine naïve, therefore the extent of the relationship between 
multimorbidity and motor severity and QoL cannot be generalised to treatment-naïve 
patients. Patients who declined to participate tended to be older [9] and may be speculated 
to have greater comorbid disease counts and impairments.. Clinically, participants with PD 
would be expected to have more multimorbidity and worse general health; however, this 
was not reflected in the results. 
Conclusion 
Multimorbidity is associated with worse QoL in patients with early PD. Effective management 
of multimorbidity is important to achieve optimal QoL in this patient cohort, and implies that 
a multidisciplinary approach to treating PD should be instigated from diagnosis and not just 
in more advanced disease.  
A longitudinal investigation of this cohort, focusing on the long-term impact of multimorbidity 
on motor severity, and QoL could clarify the influence of multimorbidity on disease 
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progression. Furthermore, given the multi-system nature of PD, the development of a PD-
specific multimorbidity measure, including the hybridisation of the medication count, non-PD 
medication count and age-adjusted CCI, may improve specificity and predictive abilities of 
such a tool.  
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Supplementary Data 
Demographics and characteristics of participants with PD and controls 
  
PD 
(n=154) 
Controls 
(n=99) 
Test 
statistic 
P value 
Mean SD Mean SD 
Age (years) 66.4 10.4 67.9 8.2 -1.3† 0.214 
Gender (Male) 
n(%) 
100 (64.9) - 54 (54.5) - -1.6* 0.099 
MoCA‡ 25.2 3.7 27.0 2.5 -3.7 <0.001 
MMMSE 28.6 1.3 29.0 1.2 -2.7 0.006 
GDS-15 2.8 2.5 1.0 1.5 -6.9 <0.001 
BMI 27.2 4.8 27.7 3.9 -1.2 0.247 
Years of 
Education 
12.8 3.8 13.1 3.4 -1.2 0.238 
NART 114.7 10.7 115.9 8.7 -0.5 0.635 
Duration of PD 
(Months) 
6.0 4.6 - - - - 
MDS-UPDRS-II 10.9 5.8 - - - - 
MDS-UPDRS-III 26.9 12.1 - - - - 
H&Y Scale, n(%) 
1 
2 
3 
4 
 
35 (22.7) 
88 (57.1) 
30 (19.5) 
1 (0.6) 
- - - - - 
PDQ-39 18.7 14.4 - - - - 
LEDD (mg/day) 178.0 148.2 - - - - 
MCI present 
n(%) 
65 (42.2) - 21 (21.2) 0.4 -3.4* 0.001 
Abbreviations: MoCA = Montreal Cognitive Assessment; MMMSE = Mini-Mental State Examination; GDS-
15 = Geriatric Depression Scale-15; BMI = Body Mass Index; NART = National Adult Reading Test; MDS-
UPDRS = Movement Disorder Society Unified Parkinson’s Disease Rating Scale; H&Y = Hoehn and Yahr 
Scale; PDQ-39 = Parkinson’s Disease Questionnaire; LEDD = Levodopa Equivalent Daily Dose; MCI = Mild 
Cognitive Impairment using 1.5SD cut off. 
All data are mean and standard deviations except where indicated. All data are non-parametric and test 
statistics are z scores from Mann-Whitney U-test except where indicated. *Chi squared test; †Independent 
t-test. Significant values indicated in bold. 
‡ n=15 did not complete MoCA. 
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